Citadel Advisors’s AtriCure ATRC Stock Holding History

Citadel Advisors’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$322K	Buy	+11,500	New	+$324K	﹤0.01%	10968
2025 Q2	–	Sell	-4,500	Closed	-$145K	–	12474
2025 Q1	$145K	Hold	4,500	–	–	﹤0.01%	10926
2024 Q4	$138K	Sell	4,500 -2,700	-38%	-$86.8K	﹤0.01%	11016
2024 Q3	$202K	Buy	7,200 +3,600	+100%	+$88.7K	﹤0.01%	10135
2024 Q2	$82K	Sell	3,600 -500	-12%	-$11.5K	﹤0.01%	11181
2024 Q1	$125K	Buy	4,100 +2,400	+141%	+$80.4K	﹤0.01%	11057
2023 Q4	$60.7K	Buy	+1,700	New	+$63.2K	﹤0.01%	11582
2023 Q3	–	Sell	-300	Closed	-$14.8K	–	14254
2023 Q2	$14.8K	Buy	+300	New	+$13.8K	﹤0.01%	12987
2021 Q3	–	Sell	-5,000	Closed	-$397K	–	13772
2021 Q2	$397K	Sell	5,000 -1,800	-26%	-$131K	﹤0.01%	10578
2021 Q1	$446K	Buy	+6,800	New	+$419K	﹤0.01%	9929
2020 Q4	–	Sell	-6,700	Closed	-$267K	–	10887
2020 Q3	$267K	Buy	6,700 +1,200	+22%	+$50.9K	﹤0.01%	8333
2020 Q2	$247K	Buy	+5,500	New	+$239K	﹤0.01%	8224
2015 Q4	–	Sell	-500	Closed	-$11K	–	8707
2015 Q3	$11K	Buy	+500	New	+$12.5K	﹤0.01%	8427

Other funds holding ATRC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Citadel Advisors's ATRC Position: Q2 2026 in Review

Citadel Advisors increased its AtriCure (ATRC) stake by 103% in Q2 2026, buying an estimated $2.53M and bringing the position to 177,339 shares worth $4.96M. The position accounts for ﹤0.01% of the portfolio, ranked #4733.

Citadel Advisors first reported a position in ATRC in Q4 2013 and has held it in 41 quarters since. The position peaked at $65.8M in Q2 2021. 252 funds tracked by Wall St. Rank hold ATRC as of Q2 2026.

Citadel Advisors held 177,339 shares of AtriCure worth $4.96M as of Q2 2026.
Citadel Advisors bought 89,992 AtriCure shares in Q2 2026, an estimated $2.53M.
AtriCure made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4733 holding.
Citadel Advisors first reported a position in AtriCure in Q4 2013 and has held it in 41 quarters since.
Citadel Advisors's AtriCure position peaked at $65.8M in Q2 2021.
252 funds tracked by Wall St. Rank held AtriCure as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.